Personalized therapy after surgery for bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial uses a test called MiniPDX, which grows a tiny sample of your tumor in mice to see which drugs work best. After your surgery, you'll receive chemotherapy chosen specifically for your cancer to help prevent it from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove bile duct cancer, and the surgery got all of the visible cancer (R0 resection).
- You are at least 18 years old and able to walk around and take care of yourself (ECOG 0 to 2).
- Your major organs (heart, liver, kidneys, brain) are working well, and you do not have serious heart problems or bleeding disorders.
- You have acceptable blood counts and liver/kidney function as shown by recent lab tests.
- You agree to use birth control during the study and for 6 months after, if you or your partner can become pregnant.
- You have not had chemotherapy or radiation therapy before this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.
This trial tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (envafolimab) for biliary tract cancer that can be removed by surgery. The goal is to prevent cancer from coming back after surgery.
This trial tests if a combination of immunotherapy (durvalumab), chemotherapy (GEMOX or GC), and a targeted therapy (lenvatinib) works better than standard capecitabine chemotherapy to prevent cancer from coming back after surgery for bile duct or gallbladder cancer.
This study tests whether combining chemotherapy and radiation therapy after surgery improves outcomes for patients with bile duct or gallbladder cancer. It's designed for patients whose surgery showed signs the cancer might come back.
This trial tests a specific chemotherapy after surgery for people with stage II or III bile duct, gallbladder, or ampullary cancer. It may help reduce the chance of cancer coming back.
This Phase 2 trial studies whether adding a PD-1 antibody plus gemcitabine/oxaliplatin (GEMOX) after surgery can lower the chance of the cancer coming back in perihilar cholangiocarcinoma. It’s for people who have had surgery with no tumor left at the cut edges, but lymph nodes showed cancer under the microscope.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.